AiViva Biopharma Initiates Phase I/II Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

AiViva Biopharma Inc announced that it had begun dosing patients diagnosed with superficial or nodular basal cell carcinoma with AIV001. AIV001 is AiViva’s novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions.